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Prevention of infections by vaccination remains a compelling goal to improve public health.
Mucosal vaccines would make immunization procedures easier, be better suited for mass
administration, and most efficiently induce immune exclusion – a term coined for non-
inflammatory antibody shielding of internal body surfaces, mediated principally by secretory
immunoglobulin A (SIgA).The exported antibodies are polymeric, mainly IgA dimers (pIgA),
produced by local plasma cells (PCs) stimulated by antigens that target the mucose. SIgA
was early shown to be complexed with an epithelial glycoprotein – the secretory compo-
nent (SC). A common SC-dependent transport mechanism for pIgA and pentameric IgM
was then proposed, implying that membrane SC acts as a receptor, now usually called the
polymeric Ig receptor (pIgR). From the basolateral surface, pIg-pIgR complexes are taken
up by endocytosis and then extruded into the lumen after apical cleavage of the receptor –
bound SC having stabilizing and innate functions in the secretory antibodies. Mice deficient
for pIgR show that this is the only receptor responsible for epithelial export of IgA and IgM.
These knockout mice show a variety of defects in their mucosal defense and changes in
their intestinal microbiota. In the gut, induction of B-cells occurs in gut-associated lym-
phoid tissue, particularly the Peyer’s patches and isolated lymphoid follicles, but also in
mesenteric lymph nodes. PC differentiation is accomplished in the lamina propria to which
the activated memory/effector B-cells home. The airways also receive such cells from
nasopharynx-associated lymphoid tissue but by different homing receptors. This compart-
mentalization is a challenge for mucosal vaccination, as are the mechanisms used by the
mucosal immune system to discriminate between commensal symbionts (mutualism),
pathobionts, and overt pathogens (elimination).
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INTRODUCTION
The existence of an external antibody system was proposed by
Alexandre Besredka at the Pasteur Institute, Paris, when he in 1919
showed that rabbits, after oral immunization with killed Shigella,
were protected against fatal dysentery irrespective of the serum
antibody titer (1). Over the last 20 years before his death in 1940,
he devoted most of his time to the study of mucosal immuniza-
tion. In 1922 Arthur Davies, through his work as a physician for
the British troops in Egypt, supported Besredka’s idea of a sepa-
rate mucosal immune system by detecting antibodies against the
dysentery bacillus in stools several days before such antibodies
appeared in serum of infected patients (2). These and other pio-
neering studies on secretory antibodies have been discussed by
Besredka (3) and Pierce (4).
A molecular basis for this field emerged when it was shown that
saliva contains immunoglobulin (Ig) molecules (5). Conclusive
evidence was not obtained, however, until the identification of dif-
ferent Ig classes was possible, and several laboratories reported that
IgA predominates in most external secretions (6). The discovery by
Thomas B. Tomasi and colleagues in USA, showing that secretory
immunoglobulin A (SIgA) exhibits unique molecular proper-
ties, further intensified investigation of mucosal immunity (7).
SIgA was found to be polymeric (mainly dimers) and covalently
associated with an 80-kDa epithelial glycoprotein initially called
“transport piece” and later named “secretory component” (SC).
It was furthermore reported by Joseph F. Hereman’s laboratory
in Belgium that the Ig class distribution of plasma cells (PCs) in
the human gut differs strikingly from that in lymph nodes and
bone marrow (8); in normal mucosal tissues, IgA+ PCs, and their
immediate precursors (plasmablasts) are ∼20 times as numerous
as IgG+ PCs.
In 1973, our laboratory provided the first direct evidence that
human mucosal IgA+ PCs produce mainly dimers and perhaps
some larger polymers (collectively called polymeric, mainly IgA
dimers, pIgA) rather than monomers (9), and in 1974 this charac-
teristic was found to be associated with co-expression of a 15-kDa
disulfide-linked polypeptide called joining (J) chain (10). In the
late 1960s we had observed that not only pIgA but also pentamers
of IgM are preferentially transferred to external secretions such as
saliva, apparently because of a common epithelial transport system
(11, 12). Secretory IgM (SIgM) in parotid saliva was subsequently
shown to be only non-covalently associated with SC (13), but in
the gut epithelium IgM was found by immunoelectron microscopy
to follow the same intracellular vesicular transfer route as pIgA
and SC, while the secretory epithelial cells apparently were devoid
of IgG (14). A shared receptor-mediated mechanism involving
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endocytosis and transcytosis therefore seemed to exist for SIgA and
SIgM formation (9, 10, 15–17). Our transport model was based
on a suggested crucial cooperation between J-chain-expressing
mucosal IgA+ (and IgM+) PCs and SC-expressing serous-type
of secretory epithelial cells (Figure 1).
EXPORT OF SECRETORY ANTIBODIES
Membrane SC is a carbohydrate-rich glycoprotein of ∼100 kDa
constitutively expressed basolaterally on secretory epithelial cells
(Figure 1), where it exhibits strong non-covalent affinity for J-
chain-containing pIgA and pentameric IgM (18). It belongs to
the Ig supergene family with five extracellular domains and is
now usually referred to as the polymeric Ig receptor (pIgR). Its
human gene has been cloned and characterized (19), and sev-
eral DNA elements could explain its remarkably high constitutive
and cytokine-enhanced expression (20). Interferon-γ (IFN-γ) was
the first cytokine shown to increase epithelial pIgR/SC expression
and it was taken to be particularly responsible for the enhanced
pIg export seen in concert with an intensified local immune
response (21). IFN-γ-responsive DNA element in the upstream
promoter and exon 1 of the pIgR gene have been identified (22),
but there are also elements responsive to regulatory factors in the
first intron (20). Altogether, both steroid hormones and proin-
flammatory cytokines can upregulate pIgR, including interleukin
(IL)-17 which is particularly abundant at mucosal sites (23).
Microbial components interacting with epithelial pattern recog-
nition receptors (PRRs), such as Toll-like receptors (TLRs), can do
the same (24).
When pIgR reaches the apical surface of the epithelial cell,
SIgA and SIgM are exocytosed after cleavage of the receptor;
only its C-terminal segment remains for intracellular degrada-
tion (Figure 1). The extracellular part of pIgR (∼80 kDa) is
exceptionally carbohydrate-rich (25), and when incorporated into
the SIg molecules as bound SC it endows particularly SIgA (where
it becomes disulfide-linked) with resistance against proteolytic
degradation (26). Excess of unoccupied pIgR is released in the
same manner by proteolytic cleavage to form so-called free SC
(Figures 1 and 2) according to the internationally recommended
nomenclature (27). This 80-kDa glycoprotein can be found in
most exocrine secretions (12), and on average ∼50% of the
exported SC occurs in a free form (28). This “sacrificial” nature
of pIgR explains the need for its high level of constitutive expres-
sion (20). Importantly, both free SC and bound SC show several
innate immune functions such as inhibition of epithelial adhesion
of certain Gram-negative bacteria and neutralization of bacterial
toxins (26). By equilibrium with bound SC, free SC in secretions
also exerts a stabilizing effect on the quaternary structure of SIgM
in which bound SC is only non-covalently linked (13).
The binding sites of pIgA and pentameric IgM initially contact-
ing the first extracellular domain of pIgR have largely been defined
(29). In addition, it has been shown that the J chain is crucial for
the initial non-covalent complexing and stabilization between the
Ig polymers and pIgR (or free SC) in in vitro experiments (18,
30). Thus, our original proposal that the J chain and pIgR/SC are
involved in a “lock and key” mechanism in the selective epithelial
export of pIgA and pentameric IgM, is now firmly established (31–
33). The J chain is normally produced preferentially by mucosal
FIGURE 1 | Receptor-mediated epithelial export of polymeric IgA (pIgA,
mainly dimers) to provide secretory IgA (SIgA) antibodies. At the
mucosal surface, SIgA antibodies together with mucus perform immune
exclusion of antigens. The epithelial polymeric Ig receptor (pIgR) is
expressed basolaterally, mainly in the intestinal crypts (glands), as
membrane secretory component (mSC) and mediates external transcytosis
of pIgA (and pentameric IgM, not shown). SIgA is released to the lumen
with bound SC by apical cleavage of pIgR, in the same manner as
unoccupied pIgR (carrying no ligand) is cleaved to provide free SC. Mucosal
plasma cells produce abundantly pIgA with incorporated J chain (IgA+ J),
which is required for high-affinity epithelial binding of the pIgR ligands.
Modified from Brandtzaeg (16).
FIGURE 2 | Generation of secretory IgA (SIgA) and free secretory
component (SC). SIgA is formed as a hybrid antibody molecule stabilized
by a disulfide bridge between the two cell products. The amount of dimeric
IgA (pIgA) produced by a plasma cell depends on its level of J-chain
expression, which generally is high in mucosal and glandular tissue. Inset
(left) shows direct demonstration of abundant cytoplasmic expression of
pIgA (p) in most plasmablasts and plasma cells in the parotid gland achieved
by in vitro affinity test with free SC on tissue section as described (9),
whereas a single cell producing only monomers (m) is seen in this field. On
average, ∼50% of SC occurring in various secretions is in a free form
(unoccupied by ligand). The immunostained panel is from Brandtzaeg (45).
PCs (34), perhaps reflecting a recent generation of their precursors
in germinal centers (GCs) of mucosa-associated lymphoid tissue
(MALT), while little or no J-chain expression would signify sev-
eral precursor rounds through GCs according to the “decreasing
potential” hypothesis (35). However, the J chain can only become
disulfide-linked to the Fc regions of IgA and IgM which carry a
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small tailpiece in their heavy (H) chains (36). When it is produced
by other PC classes (Table 1), it therefore remains in a free form
and is degraded intracellularly without being released from the
cells in detectable amounts (37, 38). That most PCs at a normal
secretory effector site contain pIgA with incorporated J chain, is
demonstrated by the fact that the cytoplasm of these cells in a
tissue section binds free SC when it is added in vitro (Figure 2).
As mentioned previously, SIgM is not secondarily stabilized
by bound SC through disulfide bonding, and its resistance to
proteolytic degradation is inferior compared to SIgA. Also, when
comparing the proportions of parotid PC classes and the IgA-to-
IgM concentration ratio in the secretion (Figure 3A), the glandular
export of pIgA is favored over that of pentameric IgM by a factor
of ∼5 (or 12-fold on a molar basis) (39). This is not explained by
different handling of the two polymers by pIgR (Figure 3B) but is
due to diffusion restriction for the relatively large IgM pentamers
through stromal matrix and basement membranes, inhibiting its
access to the basolaterally expressed pIgR. In fact, human pen-
tameric IgM shows much higher affinity for free SC in vitro than
does pIgA (30).
Of the two subclasses of IgA, IgA2 is more stable than IgA1
because the short hinge region renders it resistant to certain bac-
terial proteases (40). Molecular modeling suggests that its short
hinge also explains a rigid and non-planar structure which facil-
itates better multivalent binding of IgA2 to antigens on bacterial
surfaces (41). Therefore, it is interesting that a large proportion
(40–60%) of the IgA+ PCs in distal gut mucosa produce IgA2 (42,
43). In this respect, the salivary glands are intermediate between
the upper airways and the distal gut, a disparity that clearly reflects
regional immunoregulatory differences (34). In agreement with
the similar affinity of IgA1 and IgA2 for free SC in vitro (30),
however, both subclasses appear to be equally well exported by
pIgR into the external secretions (Figure 3A), such as parotid
saliva (44).
As alluded to previously (Figure 2), evaluation of IgA+ PCs at
secretory effector sites for J-chain expression and in vitro cytoplas-
mic affinity for free SC (marker of pIgA production), has indicated
that almost 90% of them are variably involved in production of
polymers (45). These pIgA molecules are immediately available for
the unique pIgR-driven epithelial transport system which gener-
ates both free SC and the hybrid SIgA molecule (Figures 1 and 2),
where the bound SC in a changed conformational shape covers
most of the J chain, according to recent modeling studies (41,
46). Thus, the many cartoons in the literature depicting bound
SC wrapped around the Fc portions of the two IgA subunits, are
definitely wrong.
There have been many conflicting opinions about the epithe-
lial elements expressing pIgR/SC. In our laboratory, this receptor
has been localized by immunostaining mainly to the serous-type
of epithelial cells, regardless of the mucosal or glandular body
site investigated (47–49). But it remains unknown how locally
produced pIgA and pentameric IgM molecules are directed in
their diffusion through the stromal ground substance to reach
receptor-expressing epithelial elements instead of being drained
by lymph to the blood circulation (17). Thus, there is normally
no enrichment of pIgA in thoracic duct lymph and portal vein
blood (50).
Table 1 | J-chain positivity (%) of mucosal plasmablasts and plasma
cells.
Exocrine tissue site Ig class expression
IgA IgM IgG IgD
Mammary glands 94 100 56 100
Salivary and lacrimal glands 92 100 44 (72)* 95
Normal nasal mucosa 98 100 69 100
Normal small intestinal mucosa 99 100 87 ND
*Data from IgA-deficient individuals.
ND, not determined.
Based on published data from the author’s laboratory.
FIGURE 3 | Relationship between local production of Ig isotypes by
gland-associated plasma cells and Ig transfer by secretory epithelium.
(A) Compared with the local production in the parotid gland, export of IgA
into stimulated secretion is clearly favored over export of IgM (and IgG and
IgD), whereas translocation of the two subclasses of IgA appears to
handled equally well by the glandular epithelium. (B) Comparison of
epithelial translocation of dimeric IgA (pIgA) and pentameric IgM (pIgM)
was performed in vitro with polarized MDCK cells transfected with the
human polymeric Ig receptor. Cells were incubated with 125I-labeled pIgA or
pIgM for 2 h at 4°C, washed for 10 min at 4°C, and chased at 37°C for
different times as indicated. Translocation is expressed as the cumulative
appearance of 125I-pIgA and 125I-pIgM in the apical medium. Each point
represents mean result of three filters for pIgA and pIgM translocation at
50 nM ligand concentration. Adapted from Norderhaug et al. (29).
DEFENSE MECHANISMS OF SECRETORY ANTIBODIES
The chief defense function of SIgA appears to be binding of solu-
ble or particulate antigens in the action referred to as immune
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exclusion (51). The remarkable stability of SIgA makes it well
suited to function in protease-containing secretions, and its enzy-
matic resistance seems to be enhanced when the antibody is
complexed with antigen (52). Notably, certain bacteria such as
Neisseria gonorrhoea, N. meningitidis, Streptococcus pneumoniae,
and Hemophilus influenzae produce enzymes that can selectively
cleave SIgA1 in its extended (13-amino acid) hinge region. The
same is true for oral bacteria, especially some strains of S. san-
guinis (previously S. sanguis) and S. mitior (previously S. mitis)
but also Porphyromonas/Prevotella (previously Bacteroides) and
Capnocytophaga species which are involved in periodontal dis-
ease (40). On average, at least 60% of salivary IgA consists of the
IgA1 isotype (Figure 3A), and parotid antibodies to S. mutans
occur predominantly in this subclass, whereas reactivity to lipotei-
choic acid from S. pyogenes and to lipopolysaccharides (LPS) from
Porphyromonas gingivalis (previously Bacteroides gingivalis), Bac-
teroides fragilis, and Escherichia coli is carried mainly by in the IgA2
isotype (53).
Although Fabα fragments released by the IgA1 proteases may
retain antigen-binding capacity (54), this immune reaction may
be adverse rather than protective. Such fragments may shield
microorganisms from the defense function of SIgA antibodies and
may even enhance epithelial colonization and thereby promote
invasiveness (55), whereas intact SIgA can specifically inhibit cel-
lular attachment and penetration of for instance influenza virus,
in contrast to monomeric IgA or IgG neutralizing antibodies (56).
In vivo coating of bacteria with IgA can be directly demonstrated
by immunostaining; and although this apparently does not inhibit
bacterial growth (57), it is considered to provide containment of
the microbiota and counteract invasiveness (Table 2). But bacte-
rial IgA coating is no proof of antibody reactivity because many
strains of group A or B streptococci possess Fcα receptors (58).
Nevertheless, binding of SIgA to bacteria via Fc interactions may
be of similar functional importance as Fab-mediated antibody
coating, and the same regards microbial interactions with glycans
of bound SC in SIgA (26). By affinity for mucin SIgA may also be
involved in biofilm formation (59), and it was recently reported
that mannose-containing oligosaccharides within human SIgA can
alter the virulence phenotype of Vibrio cholerae such as biofilm
formation (60).
Many identified strategies may contribute to SIgA-mediated
immune exclusion of antigens (Table 2). In addition to more effi-
cient antigen binding, complexing, and neutralization (61), SIgA
antibodies show better agglutinating properties than monomeric
IgA, which may be partly explained by interactions with mucin
(62). The combined effect of the dimeric structure and the T-
shaped Fab fragments (63) – allowing SIgA antibodies to grasp
big particulate antigens such as bacteria – can largely explain the
superior biological properties of SIgA antibodies (Figure 4). Their
function appears to be further amplified by a high level of polyreac-
tivity or cross-reactivity (64), as discussed later. Finally, in complex
with antigen the affinity of SIgA2 for as yet unknown receptor(s)
on epithelial M cells of gut-associated lymphoid tissue (GALT)
is enhanced (52), thus promoting mucosal immunity against tar-
geted antigens by “immune inclusion” which may be particularly
important in immunological integration between the mother and
her breastfed baby (65).
Table 2 | Anti-microbial effects of secretory IgA antibodies.
SIgA is dimeric/polymeric and exhibits T-shaped Fab fragments, therefore
exerting efficient microbial agglutination and virus neutralization
SIgA performs non-inflammatory extracellular and intracellular immune
exclusion by inhibiting epithelial adherence and invasion
SIgA exhibits cross-reactive (“innate-like”) activity as well as high-affinity
somatic mutants and provides cross-protection in a partially vaccinated
population (“herd protection”)
SIgA (particularly SIgA2) is quite stable (bound secretory component
stabilizes both subclasses)
SIgA is endowed with mucophilic and lectin-binding properties (via bound
secretory component in both subclasses and mannose in IgA2)
Modified from Brandtzaeg (51).
An interesting example of the potential of SIgA-mediated
immune exclusion is the experimental results obtained with
mucosal immunization against Mycobacterium tuberculosis (66,
67). The fight against tuberculosis requires new thinking and inno-
vative approaches, which are central to developing novel active or
passive immunization strategies. The possible role of SIgA in this
respect has been shown in an infection model and intranasal vac-
cination in pIgR knockout mice which are deficient in secretory
immunity (68, 69), and by nasal administration of – or bacterial
preincubation with – purified colostral SIgA from unimmunized
(naïve) women in an M. tuberculosis-based murine model (70).
INDUCTIVE SITES FOR MUCOSAL B-CELL ACTIVATION
Initial immune stimulation to generate memory/effector B cells
for mucosal pIgA responses takes place mainly in MALT struc-
tures, particularly Peyer’s patches (PPs) of the distal ileum and
other parts of GALT, such as the numerous isolated lymphoid fol-
licles (ILFs) and the appendix (71). From these inductive sites
the activated B-cells reach peripheral blood by migrating through
lymph and draining lymph nodes and subsequently extravasate
at, or are excluded from, secretory effector sites on a compet-
itive basis – depending on complementary adhesion molecules
and chemokine–chemokine receptor pairs (71, 72). The homing
is successfully accomplished when it is directed by interactions
between several dynamically regulated endothelial adhesion mol-
ecules or “addressins” and the corresponding ligands (“homing
receptors”) expressed on the memory/effector cells (Figure 5).
By such complex mechanisms, mucous membranes and exocrine
glands are furnished with locally produced antibodies, partly
in an integrated way ensuring a variety of specificities at every
secretory site, but also in a compartmentalized manner mak-
ing the secretory immune system less “common” than previously
believed (27, 34, 71).
It is not always well delineated which MALT structures are
most important for induction of SIgA responses subsequently
expressed at a specific secretory effector site, but there is convinc-
ing evidence both in animals and humans that activated B-cells
migrate from GALT to the upper aerodigestive tract and lactating
mammary glands (73–76). However, recent studies point to the
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FIGURE 4 | Synopses of the structural basis for the excellent
anti-microbial binding properties of secretory IgA (SIgA). Domain
interactions in the formation of SIgA based on data reviewed in
Norderhaug et al. (29). Non-covalent interactions are shown between the J
chain (J) and the extracellular domain 1 (D1) of bound secretory
component (SC), and covalent disulfide bonding is indicated between
cysteine 467 or 502 in D5 of bound SC and cysteine 311 in the Cα2
domain of one of the two IgA subunits. Some studies have indicated that
there may be two J chains in dimeric IgA (30). Insert to the lower left is
from modeling data for dimeric IgA1 based on X-ray and neutron scattering
in solutions published in Bonner et al. (63). Note the T-shape of the Fab
fragments, allowing for antibody binding to large particles like bacteria. V,
variable region; C, constant region; L, light chain; H, heavy chain; Fab,
fragment antigen binding; Fc, fragment crystallizable.
FIGURE 5 | Homing properties of human mucosal memory/effector
B cells. Putative scheme for compartmentalized migration of B cells
from inductive (top) to effector (bottom) sites. Depicted are more or less
preferred pathways (graded arrows) presumably followed by mucosal
B cells activated in nasopharynx-associated lymphoid tissue (NALT)
represented by palatine tonsils and adenoids, bronchus-associated
lymphoid tissue (BALT), and gut-associated lymphoid tissue (GALT)
represented by Peyer’s patches, appendix, and colonic-rectal isolated
lymphoid follicles. The principal homing receptor profiles of the
respective B-cell populations, and adhesion/chemokine cues directing
extravasation at different effector sites, are indicated (pink and blue
panels) – those operating in lactating mammary glands apparently being
shared for NALT- and GALT-derived cells. Homing molecules integrating
airway immunity with systemic immunity are encircled in red. Adapted
from Brandtzaeg (51). MEC, mucosae-associated epithelial chemokine;
TECK, thymus-expressed chemokine.
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possibility that nasopharynx-associated lymphoid tissue (NALT),
such as the unpaired nasopharyngeal tonsil (often called adenoids)
and the paired palatine tonsils in humans, may be most impor-
tant as an inductive site for mucosal memory/effector B cells in
this region (77, 78). Although it remains uncertain to what extent
these lymphoepithelial structures of Waldeyer’s ring are function-
ally comparable to rodent NALT (79), they are strategically located
to orchestrate mucosal immunity against both airborne and ali-
mentary antigens. Moreover, they are well designed for immune
induction because of their deep and branched antigen-retaining
crypts and the absence of antigen-degrading digestive enzymes.
There is, moreover, circumstantial evidence to imply that the
human GALT system differs considerably from that of NALT with
regard to B-cell precursor differentiation and/or immunoregu-
latory events involved in this process. First, a striking disparity
exists between the two regions in terms of IgD responses, partic-
ularly in IgA deficiency (34). Second, there is also a disparity in
the subclass distribution of IgA+ cells, as mentioned previously.
Although some studies have concluded that the predominance of
IgA2+ plasmablasts/PCs in the distal intestine (particularly in the
colon) can be explained by in situ switching to this subclass in the
lamina propria (80), we have found by molecular methods that
such a contribution must be negligible or absent; the IgA-subclass
profile seems, instead, to be imprinted in MALT structures before
the homing of activated B cells to secretory effector sites takes
place (Lin et al., in revision).
HOMING MOLECULES GUIDING THE MIGRATION OF
MUCOSAL B CELLS
In an S. mutans-based caries model in rats, intranasal immuniza-
tion with a recombinant bacterial fusion protein induced salivary
IgA antibodies and serum IgG and IgA antibodies (81). Also, direct
immunization of human palatine tonsils, and particularly nasal
vaccination, gave rise to local B-cell responses in tonsils and ade-
noids as well as circulating specific B cells which were excluded
from the intestinal mucosa (82). Similarly, infants dying of sudden
infant death syndrome (SIDS) were found to have overstimulated
tonsillar GCs reflected by an increased number of IgG+ and IgA+
PCs, probably caused by airway infection (83); and such acti-
vated B cells were apparently distributed in excessive numbers to
regional secretory effector sites, including the parotid glands (84),
thereby explaining the increased levels of salivary IgA and IgM in
SIDS (85).
Evidence is thus accumulating to support the notion that
human NALT supplies secretory effector sites of the upper aerodi-
gestive tract with activated pIgA+ precursor cells (78, 86). One
reason for the suggested homing dichotomy between this region
and the small intestine appears to be differences in the employed
homing molecules (72). The leukocyte integrin α4β7 is important
for B-cell extravasation into the gut lamina propria by interaction
with the mucosal addressin cell adhesion molecule (MAdCAM)-1
expressed on the intestinal microvascular endothelium (Figure 5);
but this integrin does not appear to be important for homing to
the airways and salivary glands (34). Also the involved chemokine
receptor–chemokine interactions (CCR9–CCL25 versus CCR10–
CCL28) show a striking dichotomy between the two body regions
(87). The low expression level of gut-homing molecules after
NALT immunization, particularly α4β7, has been shown in mice
to be the direct reason for exclusion of the activated B cells from
small intestinal mucosa (72). Human NALT induction induces,
instead, α4β1 interacting with vascular cell adhesion molecule
(VCAM)-1 and also the expression of the systemic homing mol-
ecules l-selectin (CD62L) and CCR7 (78). This probably reflects
that palatine tonsils and adenoids act as a “cross-road” between
mucosal and systemic immunity (Figure 5).
Sublingual immunization in mice with stimulation of B cells
in cervical lymph nodes apparently results in dissemination of
immunity by the same homing molecules as those operating after
NALT stimulation, but may be a safer approach with no possibility
for redirecting antigens/adjuvants to the brain (88, 89). Sublingual
instead of subcutaneous allergen administration is an established
alternative approach to desensitize pollen-allergic patients, and
such sublingual immunotherapy (SLIT) is now being tested also
for food allergens. Interestingly, in a SLIT trial for peanut allergy,
6 of 10 patients showed significant induction of IgA (and SIgA)
peanut-reactive antibodies in saliva (90).
Still there is a need for more extensive clinical studies, perhaps
focusing collectively on the adenoids/palatine tonsils and cervical
lymph nodes, in addition to GALT, as inductive lymphoid tissue
for regional SIgA responses. For instance, some 20–30 years ago,
reports relevant for human NALT suggested reduced salivary IgA
levels in children with recurrent tonsillitis (91) or with adenoid
hyperplasia (92). Decreased J-chain expression is a consequence
of recurrent tonsillitis, and to a lesser extent adenoid hyperpla-
sia, implying that chronic inflammation may compromise the
potential of Waldeyer’s lymphoid ring to furnish the regional SIgA
system with pIgA+ plasmablasts (78).
CELLULAR AND MOLECULAR INTERACTIONS IN ANTIBODY
INDUCTION
Mucosa-associated lymphoid tissue structures are principally sim-
ilar to lymph nodes but they are not encapsulated and have no
afferent lymph supply. Antigens for immune stimulation there-
fore have to be taken up through a follicle-associated epithelium
which is equipped with very thin M (“microfold” or membrane)
cells which are specialized for sampling and transport of especially
particulate antigens like bacteria (34).
THE GERMINAL CENTER REACTION
Naïve T and B lymphocytes enter MALT structures through spe-
cialized high endothelial venules. The primary lymphoid follicles
are aggregates of such recirculating B lymphocytes (sIgD+IgM+)
which pass into a network formed by antigen-capturing follicu-
lar dendritic cells (FDCs). The origin of FDCs remains obscure,
but both their development and the clustering that allows follicle
formation depend on lymphotoxin (LT) signaling (93). Experi-
mental evidence suggests that the B cells are one important LT
source (94–96). Among the actions of the soluble homotrimer
LTα, are augmentation of B-cell proliferation and expression of
adhesion molecules, while mice deficient in transmembrane LTβ
have no detectable FDCs (97).
The GC reaction turns the primary into a secondary
follicle – polarized into a “dark zone” (dominated by proliferating
centroblasts) and a “light zone” (dominated by centrocytes) where
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cells proceed to memory B-cell or terminal plasmablast/PC differ-
entiation (Figure 6). In humans, this process has been extensively
studied in tonsils (98), but much relevant mechanistic information
relies on observations of lymph nodes and spleen from immu-
nized animals (99). In general, GCs are of vital importance for T
cell-dependent stimulation of conventional (B2) B cells, affinity
maturation of B-cell receptor (BCR), and Ig-isotype switching.
This means that the decision to make pIgA with co-expressed J
chain has to take place in the GCs of MALT; but it remains elu-
sive why PPs are superior in this respect (34) – as reflected in the
high density of plasmablasts/PCs present in the intestinal lamina
propria (Figure 7).
Naïve B cells that leave the primary follicles are first stimulated
in the T cell zone just outside the follicle by cognate interac-
tions with activated CD4+ T cells, which have been presented
with processed antigen by MHC class II-expressing interdigitat-
ing DCs (100). In an interplay between the chemokine receptors
CXCR5 and CCR7 and the G protein coupled receptor for EBV-
induced molecule 2 (EBI2, also known as GPR183), further B-cell
differentiation depends on the tissue niche where the cells end
up – low-affinity extrafollicular PCs or high-affinity memory B
cells and GC plasmablasts/PCs (101, 102). For the latter fate, there
seems to be a BCR affinity-based pre-GC checkpoint operating in
the cognate interaction between B and T cells taking place adjacent
to the follicle (103). As described for human tonsils (104), those
B cells that escape this selection re-enter the follicle and become
proliferating sIgD+IgM+CD38+ GC “founder cells” forming the
dark zone (Figure 6). A critical step allowing this decision seems
to be downregulation of surface-expressed EBI2 (105).
The extrafollicular B cells are initially stimulated to produce
unmutated IgM (and some IgG) antibody which binds circulating
antigen with low affinity. Although still somewhat unclear, it
seems that some of these cells use their complement receptors
to carry opsonized antigen or immune complexes into the follicles
to become deposited on FDCs (106). Antigen is retained in this
network for prolonged periods to maintain B-cell memory (35).
A role for IgM in the induction of secondary immune responses
with antibody affinity maturation, has been strongly supported by
observations in knockout mice lacking natural (“non-specific”)
background IgM antibodies (107).
It remains elusive which factors govern the GC decision for the
selected high-affinity memory/effector B cells to go into terminal
differentiation to become plasmablasts/PCs (Figure 6); but it is
known that the transcription factor paired box protein-5 (Pax5)
represses genes associated with PC differentiation and function,
while expression of B lymphocyte-induced maturation protein-1
(Blimp-1) is required for such development to take place (108). It is
also clear that the complement receptors CR1/CR2 (CD35/CD21)
play a crucial role in the GC reaction by acting as a signal-
transducing complex. CD21 is expressed abundantly on both B
cells and FDCs, and may thus function not only by localizing anti-
gens to the FDCs but also by lowering the threshold of B-cell
activation via recruitment of CD19 into the BCR (109).
Activation of complement on FDCs is controlled by regulatory
factors when these cells retain immune complexes (Figure 6), but
some release of inflammatory mediators may cause edema that
facilitates dispersion of FDC-derived “immune complex-coated
FIGURE 6 | Immune events taking place in the dark and light zones of
human germinal center in secondary lymphoid follicle. The “germinal
center founder cells” receive their initial stimulation through cognate
interaction with activated CD4+ helper T cells just outside the lymphoid
follicle before they enter it to become proliferating centroblasts forming the
dark zone. Affinity maturation of sIgM as part of the B-cell receptor is
achieved after somatic hypermutation by competition for antigen presented
in ICs on FDCs. Antigen taken up by the B cells is further presented in a
cognate fashion to TFH cells, which also receive stimulatory signals from
GCDCs. The activated TFH cells act on the B cells with their cytokines,
thereby mediating expansion of high-affinity B-cell clones in the light zone.
Further details are discussed in the text. sIg, surface immunoglobulin; bcl-2,
anti-apoptotic B-cell lymphoma protein; IC, immune complex; FDC, follicular
dendritic cell; GCDC, germinal center dendritic cell; HLA-II, HLA class II
molecule; TCR, T cell receptor; TFH, follicular helper T cell; CD40L/CD40,
costimulatory molecules.
FIGURE 7 | Average tissue densities of plasmablasts/plasma cells
producing different Ig classes at various normal secretory tissue sites
as indicated. Representative areas illustrating merge of
immunofluorescence staining (see color key) are shown for submandibular
gland and colonic lamina propria. Based on published data from the author’s
laboratory.
bodies,” or iccosomes, thereby enhancing the BCR-mediated
uptake of their contained antigens by B cells with sufficient affinity
(110, 111). The antigen will next be presented in a cognate fash-
ion by these B cells to special follicular T helper (TFH) cells (112)
which in this manner are stimulated to secrete cytokines – partic-
ularly IL-21 – driving the expansion of the selected high-affinity
B-cells (Figure 6). The capacity of TFH cells to secrete IgA-switch
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factors such as transforming growth factor (TGF)-β, and the local
availability of the vitamin A metabolite retinoic acid, are proba-
bly important for the IgA-inducing capacity of a particular MALT
structure (51, 71).
ALTERNATIVE INDUCTION AND RECRUITMENT OF MUCOSAL B CELLS
Several components of the innate immune system, in addition
to complement, may be involved in the GC activity, such as the
cytokines A Proliferation-Inducing Ligand (APRIL) and B-cell-
Activating Factor of the TNF Family (BAFF). Under certain con-
ditions, IgA differentiation driven by gut bacteria may even bypass
the usual sIgM (or sIgD)-BCR and T cell requirement (113) – that
is, CD40–CD40L/CD154 interactions (Figure 6). Nevertheless, in
mice experiments there always appears to be a dependency on
some follicle-like aggregates of B cells (114) which, interestingly,
may lack antigen-retaining FDCs and GCs (115, 116). Normally,
however, the GC reaction and BCR affinity maturation are dri-
ven by competition for a limited amount of available antigen on
FDCs, which may be governed via feedback from the pressure of
antibodies produced by GC-derived plasmablasts/PCs (117). An
additional innate drive may be particularly relevant for the numer-
ous ILFs (71), and the B-cells resulting from mechanisms such as
superantigen stimulation may survive with a restricted repertoire
and rather low affinity (118).
In mice, the peritoneal cavity with its omentum is recog-
nized as a non-MALT compartment where precursor cells for
IgA production are generated (119), perhaps providing up to
50% of the intestinal IgA+ PCs (120). The precursors are self-
renewing sIgM+ B1 (CD5+) cells, which can give rise to polyre-
active (“natural”) SIgA antibodies, particularly directed against
polysaccharide antigens from commensal bacteria as a result of
T cell-independent responses (115). The substantial capacity of
these B cells to produce IL-10 makes this leukocyte population an
interesting candidate for immunoregulatory involvement (121).
However, the relationship of murine B1 cells to the conventional
bone marrow-derived B2 cells remains elusive. Notably, rather
than being encoded only in germline, B1 cells from mice may
show considerable somatic hypermutation (SHM) of Ig H-chain
V-region (VH) genes as a sign of selection (122, 123).
It is controversial where the murine B1 subset differentiates
to the IgA phenotype, although the intestinal lamina propria has
been suggested as a class-switch site (124, 125). Notably, however,
there is no evidence to suggest that peritoneal B1 cells contribute
to mucosal IgA production in humans (126, 127), where a sim-
ilar subset of B cells has not been conclusively defined. A minor
subset of CD43+CD27+ B1-like human cells has recently been
characterized in functional terms, but there is no indication that
it contributes to mucosal immunity (128). Nevertheless, con-
siderable levels of polyreactive or cross-reactive SIgA antibodies
directed against self as well as microbial antigens occur in human
external secretions (129). One reason for this could be bacterial T
cell-independent polyclonal activation of GALT.
B-CELL FATE AT THE SECRETORY EFFECTOR SITE
B-cell homing to different effector sites seems to be antigen-
independent, but topically available antigens may nevertheless
contribute to local retention, proliferation, and differentiation of
the extravasated cells. As reviewed elsewhere, experiments in gene-
manipulated mice have suggested that signaling through LTβR
on lamina propria stromal cells is necessary for the persistence
of IgA+ plasmablasts/PCs in intestinal mucosa (34). In addition,
PC retention and survival depend on a variety of cytokines and
chemokines/chemokine receptors as well as adhesion molecules,
including the extracellular matrix receptor CD44 expressed at high
levels on post-GC B cells. However, the factors triggering termi-
nal B-cell differentiation at secretory effector sites remain elusive,
although IL-5, IL-6, and IL-10 may be particularly important.
Notably, as evidenced in the multiple-intestinal-loop model in
lambs, topical exposure to antigen has a marked impact on site-
specific accumulation of specific IgA+ PCs, thereby influencing the
observed B-cell homing pattern but without imposing any selec-
tivity on the extravasation step of memory/effector cells. Thus,
GALT-derived blasts have been shown to home to presumably
antigen-free neonatal intestinal mucosa and to fetal gut grafted
under the adult kidney capsule of experimental animals.
Antigen-driven proliferation of IgA+ B cells has been observed
in intestinal lamina propria of experimental animals, especially in
the crypt regions (130). This is the level where most IgA+ PCs
occur also in the human gut (131), and scattered sIgA+ memory
cells with a proliferative potential are present in human intestinal
lamina propria (132). Also, local clonal expansion of precursors
for IgA PCs has been reported on the basis of detected IgHV
sequences in human ileal mucosa (133), but the dependency on
ILFs is difficult to evaluate in such experiments (113). Thus, rectal
immunization elicits particularly high levels of IgA antibodies in
colorectal secretions and feces both in experimental animals and
humans, apparently reflecting enhanced stimulation by combined
exposure of ILFs and lamina propria to the same antigen (34).
Human intestinal IgA+ plasmablasts/PCs are special in that
they express surface IgA with a functional BCR and therefore may
be modulated in situ by antigens with potential implications for
their survival and regulation (134, 135). It has been suggested that
the half-life of PCs varies from a few days to several months, and
those ending up in the gut may be particularly short-lived (35).
Notably, however, results obtained with isolated PCs may be mis-
leading (108). Thus, at least a fraction of human duodenal PCs are
quite long-lived in vitro, but only when cultured in whole tissue
fragments (136), in agreement with the above cited mouse experi-
ments showing IgA+ PC persistence depending on lamina propria
stromal cells.
A proliferation-inducing ligand expressed outside of MALT
structures may contribute to the survival of lamina propria PCs
similarly to the role of BAFF in the bone marrow (137). In addi-
tion, the impact of luminal antigens on the conventional B2 cell-
dependent effector arm of the SIgA system is most likely mediated
largely via “second signals” from activated CD4+ T cells. Com-
partmentalized variables in this process could be a high density
of MHC class II molecules (138), allowing only trace amounts
of foreign antigens or anti-idiotypic antibodies to elicit sufficient
second signals for B cells. Interestingly, in human salivary and lac-
tating mammary glands where there is little exposure to exogenous
antigens, IgA+ PCs accumulate preferentially adjacent to HLA-
DR-expressing epithelial ducts (139, 140), while serous-type acinar
cells produce CCL28 which attracts IgA+CCR10+ plasmablasts
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(141). Nevertheless, the density of PCs at various secretory effec-
tor site reflects topical availability of exogenous antigens, which is
high in the gut and lacrimal glands (Figure 7) – the latter secretory
site being connected to the heavily antigen-exposed conjunctiva
with several small ducts.
SPECIFIC AND CROSS-REACTIVE ANTIBODIES TO
COMMENSALS
In the germ-free appendix model in rabbits, it was shown that
only selected commensal bacteria are really efficient in promot-
ing GALT development, and that this ability depended on certain
stress responses in the same bacteria, suggesting a non-specific
impact on GALT (142). Another study concluded that commensal
bacteria could promote the GC reaction in PPs and MLNs by inter-
acting with innate immune receptors, thus being independent of
BCR engagement (143). These experiments help to explain how
the gut microbiota might drive production of large amounts of
IgA with a restricted BCR repertoire and the capacity to bind with
low affinity to redundant epitopes of commensal bacteria (144).
T CELL-DEPENDENT AND -INDEPENDENT RESPONSES
Microbial substances called Type 1 T cell-independent (TI-1) anti-
gens are directly mitogenic for B cells – including sugars, lipid
structures, and certain nucleic acids. Type 2 T cell-independent
(TI-2) antigens, on the other hand, are not by themselves mito-
genic but cause extensive cross-lining of BCR by repeating epi-
topes; their B-cell activation is exerted through synergy with sol-
uble factors (e.g., cytokines) and interaction with various types of
accessory cells. There are notable species differences in the mech-
anisms involved; for instance, while LPS acts as a TI-1 antigen
on mouse B cells, it acts as a TI-2 antigen on human B cells.
Interestingly, microbial polysaccharides may also function as T
cell-dependent antigens and exert profound homeostatic effects on
the immune system by stimulating CD4+ T cells after being pre-
sented by DCs on MHC class II molecules. Thus, it has been shown
in germ-free mice monocolonized with the ubiquitous gut com-
mensal B. fragilis, that a single bacterial polysaccharide may exert
a striking impact both on lymphoid organogenesis and immune
modulation (145).
It is well established that the gut microbiota is critically required
for activation of GALT with normal intestinal PC development
(146), although food proteins also are important for the matura-
tion of the mucosal immune system (147). There is increasingly
awareness of the interdependence of diet, commensal bacteria,
and immunity (148). Interestingly, because intestinal commen-
sals apparently contribute quite substantially to the shaping of the
BCR repertoire of the host, the speculation has been raised that
perhaps the GC reaction originated evolutionary in GALT to gen-
erate a protective antibody repertoire that was not antigen-specific
but rather cross-reactive (149).
The indigenous microbiota might in this context act as poly-
clonal B-cell activators through several mechanisms, including
TLR signaling (150). Experimental studies have attempted to
dissect mechanistically this concept by analyzing the intestinal
immune response in germ-free mice after monoassociation with a
variety of non-invasive, commensal bacteria (151, 152). It was gen-
erally found that these microbes induced a GC reaction in GALT
with generation of IgA+ plasmablasts/PCs which accumulated in
the lamina propria and produced both “natural” polyreactive (or
cross-reactive) and specific IgA. Individual bacterial species were
shown to differ, however, with regard to the maximal amount
of total IgA induced and the fraction that could be shown to
be specific for antigens of the colonizer (153). All tested bacteria
apparently elicited a waxing followed by a long-term waning IgA
response, which was accompanied by a GC reaction that notably
showed a much more rapid development as well as decline. This
could be attributed to the “shielding” of GALT from microbial
antigens by the production of specific SIgA antibodies, because of
the relatively long-term persistence of both specific and “natural”
IgA-producing PCs in the lamina propria.
Such homeostatic immune modulation has been particularly
well documented with segmented filamentous bacteria (SFB,
related to Clostridia), which become a major gut colonizer of the
distal ileum of mice after weaning. Colonization of formerly germ-
free weanlings resulted in a transient GC reaction in GALT and
seeding of the lamina propria with IgA+ plasmablasts, providing
an SIgA level comprising 50–70% of that seen in conventional
mice; but notably, only about 1% of this IgA showed specificity for
the SFB (154, 155).
IMMUNOLOGICAL MEMORY AND HOMEOSTASIS
Several uncertainties need to be solved before full understanding
of the biology of the mucosal IgA system is achieved, and one
of the open questions concerns the specificity of the intestinal
immune response (113). Monoassociation of germ-free mice with
SFB, followed by super-colonization with Morganella morganii
after 100 days, induced little change in production of total intesti-
nal IgA although the specific response to M. morganii increased
20-fold compared to that against SFB (154). The chronic GC reac-
tion observed in GALT of conventional mice is therefore most
likely caused by continuous exposure of the gut to novel micro-
bial antigens. Thus, germ-free mice monoassociated with the
comensal B. thetaiotaomicron showed that specific SIgA antibodies
directed against a single epitope (capsular polysaccharide A, PSA)
inhibited activation of innate response markers such as oxidative
burst and NFκB, thereby inducing crucial modulation of immune
homeostasis in the gut as well as microbial antigenic drift (156).
Furthermore, when germ-free mice were colonized with an
E. coli mutant, and then exposed to other commensal gut bac-
teria, the memory IgA response to E. coli was dampened by
attrition, suggesting adaptation of secretory immunity to the
predominant microbial epitopes (157). Thus, the sustained col-
onization of gut bacteria exhibiting novel epitopes may provide
the necessary chronic bystander stimulation of previously induced
cross-reactive and specific IgA production. SIgA antibodies can
hence control the intestinal microbiota in a non-inflammatory,
symbiotic, or mutualistic relationship with the host (158, 159).
Notably, at least one fourth of the IgA+ PCs in human ileal
lamina propria have been shown to produce polyreactive anti-
bodies, which nevertheless were found to be somatically mutated
with signs of antigen-driven selection (160). Other studies have
shown that IgA autoantibodies produced in duodenal mucosa
of patients with celiac disease are of high affinity but with lit-
tle adaptation by SHMs, exhibiting mainly a germline repertoire
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(161). In this context it is of considerable interest that mouse
experiments recently indicated the presence of two disparate dif-
ferentiation pathways for memory B cells – one dedicated to
generation of high-affinity somatic antibody mutants, and the
other with preserved germline specificities to arm the host for
rapid responses to encountered variants of potentially dangerous
antigens (162) – perhaps including commensals with the potential
of causing disease, so-called pathobionts (159, 163).
The near-germline feature is characteristic for the IgA reper-
toire of human neonates (164), as also reflected in neonatal
secretions (165). This situation is followed postnatally by a slow
immune maturation with a SHM frequency of IgA VH-gene tran-
scripts up to 25% of the adult level at around 5 months of age
(164). Both the duodenal and the parotid PC frequency of IgA
VH mutations of adults is much higher than that in adult human
spleen, apparently because of the constant antigenic pressure on
MALT (166). In clean laboratory rats, however, a more restricted
IgA repertoire (near germline) was revealed in salivary glands
than in the distal small intestine, probably reflecting the regional
difference in bacterial load (167).
HOW CAN SECRETORY ANTIBODIES DISCRIMINATE
BETWEEN COMMENSALS AND PATHOGENS?
Classical immunological B-cell memory depends on T cell-
dependent and long-lived clones which have proliferated in GCs
after antigen recognition on FDCs, with further maturation of
BCR affinity by point mutations in the V(D)J exons of Ig H and
Ig light (L) chains. This process of SHM may be enhanced when
antigen recall drives B cell to re-enter the dark zone for a new GC
cycle (Figure 6), or to enter a preformed follicle after exit from
the GC (168). Attempts have been made to characterize murine
memory B cells by their transcriptional program in relation to Ig
isotype (169) as both SHM and class-switch recombination (CSR)
depends on activation-induced cytidine deaminase (AID) which
targets specific DNA motifs in the B cell (170, 171). However, char-
acterization of human memory B cells has mainly been based on
phenotyping and the molecular history of SHM and proliferation
(172). CD20+CD27+ B cells have been taken to represent memory
cells and their expansion in children between 4 and 18 months of
age was found to be related to gut colonization with E. coli and
bifidobacteria (173).
With regard to circulating IgA+ B cells, the CD27-expressing
subset was indeed considered the best memory candidate with
signs of a prolonged AID impact during multiple immune
responses, most likely involving MALT (172). However, the same
authors also reported the presence of a minor subset of blood
CD27−IgA+ B cells which seemingly were completely T cell-
independent and showed molecular similarities to IgA+ B cells in
colonic mucosa. This finding was deemed to support the notion
that IgA2-producing PCs in the distal human gut develop in the
lamina propria by direct CSR from IgM to IgA2 in a T cell-
independent manner (80). As alluded to previously, this view has
been refuted by our recent molecular study of IgA-subclass switch-
ing in intestinal effector sites compared with inductive sites (Lin
et al., in revision).
Although mucosal IgA responses to commensal bacteria may
be multi-centered, of low affinity and diverse, oral immunization
of mice with a cholera toxin-adjuvanted novel antigen was recently
shown to result in a strongly oligoclonal response of affinity-
matured IgA+ B cells (174). Interestingly, it was found that the
response was highly synchronized throughout the entire intestine
by involving multiple PPs. Thus, by reutelizing already existing
CGs, antigen-specific B cells would be subjected to clonal expan-
sion and SHM, probably in the manner discussed previously. This
process was shown to require antigen recall by multiple immu-
nizations, and the study helps to clarify mechanisms underlying
the functional flexibility of mucosal anti-microbial IgA responses:
from “natural” polyreactive (or cross-reactive) low affinity to a
specific high-affinity “classical” response – a distinction that is a
major challenge to mucosal vaccine design (113).
The difficult issue of affinity maturation of mucosal B cells
and how the mucosal immune system can distinguish between
the indigenous microbiota and overt exogenous pathogens has
been discussed in several recent articles (175–177). The mucosal
barrier and its reinforcement by SIgA, as well as the mucosal
immunoregulatory network, require both adaptive and innate
induction by antigens and conserved microbe-associated mole-
cular patterns (MAMPs) – the latter activating germline-encoded
cellular PRRs such as TLRs (178, 179). It is elusive how such recep-
tors would be able to discriminate between signals provided by
MAMPs from commensals and MAMPs from pathogens (previ-
ously called pathogen-associated molecular patterns, PAMPs); but
this distinction is clearly required to elicit tolerogenic versus proin-
flammatory immune responses needed for protection against inva-
sive infections (Figure 8).Various scenarios may be visualized – the
most likely being that overt pathogens, in addition to signal-
ing through PRRs and BCRs, exhibit special danger signals, or
immune evasion mechanisms related to the pathogenicity – that
FIGURE 8 | Hypothetical depiction of how the intestinal immune
system handles symbionts and potentially pathogenic residents
(pathobionts) of the commensal microbiota versus overt exogenous
pathogens. Secretory IgA (SIgA) antibody levels against commensal
bacteria may go in waves because of epitope drift and shielding of
gut-associated lymphoid tissue from antigen uptake. The overall affinity of
SIgA antibodies probably increases with age and may be enhanced or
reduced against pathobionts during dysbiosis, and particularly raised by
persistent stimulation with overt pathogens. One goal of mutualism with
commensals is mucosal barrier reinforcement by mechanisms listed such
as SIgA export and induction of regulatory T cells, whereas pathogens
exhibit various virulence mechanisms to break the barrier.
Frontiers in Immunology | Mucosal Immunity August 2013 | Volume 4 | Article 222 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brandtzaeg Secretory IgA antibodies
is, factors determining virulence and invasiveness (180–182), or
so-called effector-triggered immunity (183, 184), while compe-
tition for metabolically shared nutrients may also be involved
(159, 185, 186).
WHAT DOES ANTIBODY COATING OF COMMENSALS MEAN?
In vivo coating of bacteria with IgA present in external secretions
can be directly demonstrated by immunostaining (Figure 9A);
and although this apparently does not inhibit bacterial growth
(57), it is considered to provide containment of the microbiota,
counteract invasiveness, and contribute to immune homeostasis
(24, 51).
In human feces, some 40% of the anaerobic bacteria are nor-
mally coated with IgA (187) and this phenomenon can be observed
in early childhood (188). Such IgA containment of commensals,
without eliminating them, is probably important for the mutual
host–microbe interaction,contributing to sustainable homeostasis
by dampening proinflammatory signaling in the host and provid-
ing an immune pressure on commensal bacteria (159, 189). This
results in antigenic drift without altered composition of the micro-
biota, or so-called dysbiosis (156, 190). Most likely this IgA coat
largely represents “natural” cross-reactive antibodies (116, 191)
but may also depend on innate properties of SIgA, as discussed
previously. In mouse experiments with Salmonella typhimurium
infection it was found that bacteria coated with such “natural” IgA
showed reduced shedding and less liability to horizontal spreading
by the fecal-oral route (192).
In mice, the IgA coating of gut bacteria has been shown to be
unrelated to the total amount of SIgA exported to the intestinal
lumen, suggesting that a specific reaction is involved (193). Also,
other recent mouse experiments demonstrated that the commen-
sal coating with IgA in feces depended on appropriate clonal B-cell
selection and affinity maturation in GCs of GALT, and perhaps to
some extent also in the lamina propria (190). Thus, this finding
showed that the coating to a substantial degree reflects a specific
IgA response. It has therefore been speculated that pathobionts
might show increased IgA coating in the gut lumen. This idea is
supported by findings in patients with inflammatory bowel dis-
ease, where there is dysbiosis (159, 194) and the fraction on anaer-
obic bacteria with IgA is raised to 65%, with 45% also carrying
IgG (195). Thus, increased antibody coating could reflect dysbiosis
(Figure 8). However, in celiac disease, where there is also dysbio-
sis, the IgA coating of fecal bacteria is significantly reduced (188).
So the biological significance of this phenomenon remains uncer-
tain, and the degree of IgA coating might reflect a combination of
innate and specific bacterial binding properties of SIgA.
Altogether, SIgA does not seem to cause clearance of commen-
sal bacteria, but controls in various ways their colonization and
inhibits the penetration of agents that could potentially cause
hypersensitivity reactions or infection (24). In the absence of B
cells, or when IgA is lacking, the intestinal epithelium of mice will,
in response to commensal bacteria, upregulate in an NFκB- and
interferon-dependent manner its innate defense (24, 189), and this
could be at the expense of expression of genes that regulate fat and
carbohydrate metabolism (196). As a consequence, the epithelial
gene signature might correlate with the development of lipid mal-
absorption (197). The intestinal epithelial barrier is a cross-road
FIGURE 9 | IgA coating of commensal bacteria may modulate mucosal
immunity and metabolism. (A) Direct immunofluorescence staining of
bacterial sediment from whole saliva to demonstrate in vivo IgA coating.
Contaminating epithelial cell is faintly visualized because of
autofluorescence. Numerous cocci (mainly diplococci) – partly adhering to
epithelial cell – have bound IgA, which also decorates older cell-wall
segments of streptococci forming long chains, whereas new crosswalls
formed by growth in vitro after sampling are negative as indicated. Adapted
from Brandtzaeg et al. (57) (Original magnification: ×2000). (B) In healthy
individuals, IgA+ mucosal plasma cells produce dimers with J chain
(IgA+ J) which are exported to the epithelial surface by the polymeric Ig
receptor (see Figure 1). Secretory IgA binds to commensal bacteria, and
the IgA-coated bacteria modulate mucosal immunity and homeostasis by
delivering signals through innate microbial sensors (red) such as pattern
recognition receptors on the epithelial cells. In addition to enhancing innate
defense through immune pathways controlled by interferon (IFN) cytokines,
these signals also regulate the intake of food lipids through metabolic
pathways controlled by the transcription factor Gata4. When IgA is lacking
(not shown), the gut epithelium upregulates its expression of
IFN-dependent innate defense genes to compensate for the lack of
adaptive IgA immunity. This upregulation leads to a downregulation of the
genes controlled by Gata4 (196). The resulting gene imbalance impairs the
epithelial absorption of lipids, such as cholesterol, resulting in metabolic
disorders with reduced leptin levels and fat storage. Modified from Chorny
and Cerutti (197).
between surface defense and nutrition, and SIgA is apparently
essential to keep the balance between these two functions and
thus maintain mucosal homeostasis (Figure 9B). Lack of SIgA
probably explains that patients with common variable immunod-
eficiency may have a similar gene expression profile in their duo-
denal mucosa and show malabsorption with fatty stools (196) –
despite frequent surface defense compensation with increased
intraepithelial lymphocytes, particularly the CD8+ subset (198).
CONCLUDING REMARKS
Secretory immunoglobulin A constitutes the largest humoral
immune system of the body and performs antigen exclusion
at mucosal surfaces and neutralizes virus and endotoxin within
epithelial cells without causing tissue damage (24, 199). The
enormous innate drive of the mucosal immune system does not
only enhance anybody diversity but also immunological mem-
ory. Mainly by its extensive polyreactivity, innate-like SIgA is
persistently containing commensal bacteria outside the epithelial
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barrier; but by increased antibody affinity SIgA can also tar-
get invasion of pathogens and penetration of harmful antigens
after mucosal infection or vaccination. Host resistance to toxin-
producing bacteria such as V. cholera and enterotoxigenic E. coli
seems to depend largely on SIgA, and so does herd protection
against horizontal fecal-oral spread of enteric pathogens under
naïve or immunized conditions – with a substantial innate impact
both on cross-reactivity and memory.
Like natural infections, live attenuated vaccines or adequate
combinations of non-replicating vaccines and mucosal adjuvants
administered by the oral route to target GALT, give rise not only
to SIgA antibodies but also to longstanding serum IgG and IgA
responses (199). However, there is considerably disparity with
regard to migration of memory/effector B cells from mucosal
inductive sites to secretory effector sites and systemic immune
organs. Also, although immunological memory is generated after
mucosal priming, this may be masked by a self-limiting response
shielding the inductive lymphoid tissue in the gut. The intranasal
route of vaccine application targeting NALT may be more advan-
tageous for certain infections, but only if successful stimulation is
achieved without the use of toxic adjuvants that might reach the
central nervous system (200). The degree of protection obtained
after mucosal vaccination ranges from reduction of symptoms to
complete inhibition of re-infection. In this scenario, it is often dif-
ficult to determine the relative importance of SIgA versus serum
antibodies, but infection models in knockout mice strongly sup-
port the notion that SIgA exerts a decisive role in protection and
cross-protection against a variety of infectious agents.
Nevertheless, relatively few mucosal vaccines have been
approved for human use, and more basic work is needed in vac-
cine and adjuvant design, including particulate or live-vectored
combinations (200). It is a fundamental problem in this field that
clinical trials are risky and expensive, so much of the basic work
has to be performed in experimental animals such as mice. There
are always difficulties in knowing to what extent immunological
information obtained in animals can be directly transferred to
human application. Thus, considerable species differences exist
in subsets of APCs and also with regard to the SIgA system.
For instance, human hepatocytes do not express pIgR whereas
rodent hepatocytes do (17). As a consequence, a large proportion
of SIgA in the lumen of the upper small intestine of these animals
originates from peripheral blood because the liver continuously
“pumps” circulating pIgA into bile after its complexing with SC.
It is therefore difficult to know to what extent SIgA antibodies in
rodent gut fluid reflect a local mucosal immune response. Ulti-
mately, though, the great efforts that are currently invested in
developing novel mucosal vaccines and adjuvants will hopefully
enhance the possibilities to exploit the SIgA system in mankind’s
fight against infectious diseases, and thereby improving global
health (200).
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